Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) FCF Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed FCF Margin for 9 consecutive years, with 172.2% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 3667.0% to 172.2% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 338.74% through Dec 2025, down 19174.0% year-over-year, with the annual reading at 338.74% for FY2025, 17321.0% down from the prior year.
  • FCF Margin for Q4 2025 was 172.2% at Marker Therapeutics, up from 221.9% in the prior quarter.
  • The five-year high for FCF Margin was 300.39% in Q2 2022, with the low at 2679.73% in Q3 2023.
  • Average FCF Margin over 4 years is 499.32%, with a median of 222.99% recorded in 2023.
  • The sharpest move saw FCF Margin plummeted -214829bps in 2023, then surged 274190bps in 2024.
  • Over 4 years, FCF Margin stood at 537.31% in 2022, then skyrocketed by 58bps to 224.09% in 2023, then increased by 7bps to 208.86% in 2024, then grew by 18bps to 172.2% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 172.2%, 221.9%, and 218.11% for Q4 2025, Q3 2025, and Q2 2025 respectively.